Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease

SYCUME® delivers strong Phase 3 results for inactive TED, supporting Innovent's China market lead.

What the company is saying

Innovent Biologics is highlighting the successful achievement of primary and key secondary endpoints for SYCUME® (Teprotumumab N01 Injection, IBI311) in the Phase 3 RESTORE-3 trial for inactive thyroid eye disease (TED) in China. The company frames SYCUME® as the first IGF-1R antibody drug in China and only the second worldwide, emphasizing its role in addressing a 70-year treatment gap. The messaging stresses statistically significant efficacy, a favorable safety profile, and the drug’s inclusion in the National Reimbursement Drug List as of January 1, 2026, which is positioned as a major accessibility and cost milestone. Quotes from Professor Zhongyan Shan and Dr. Lei Qian reinforce the clinical and strategic importance, with language focused on disease management, patient impact, and Innovent’s leadership in the space. The announcement also references Innovent’s broader pipeline, with 20 launched products, 1 asset under NDA review, 5 in Phase 3 or pivotal trials, and 19 in early clinical stage, plus over 30 global partnerships valued at over RMB 350 billion. The tone is confident, with the company presenting these results as a milestone for both clinical practice and commercial positioning.

What the data suggests

The RESTORE-3 trial enrolled 116 Chinese participants with inactive TED, randomized approximately 2:1 to IBI311 or placebo. At Week 24, the proptosis response rate in the IBI311 group was 60.4%, compared to 23.5% for placebo, a treatment difference of 36.9 percentage points (p = 0.0003). The least squares mean change in study eye proptosis distance was -1.88 mm for IBI311 versus -0.88 mm for placebo (treatment difference: -1.00 mm; p < 0.0001). In non-study eyes, response rates were 46.0% for IBI311 and 19.8% for placebo (p = 0.0071), with LS mean changes of -1.77 mm and -0.91 mm, respectively (p < 0.0001). The trial population had a baseline mean proptosis of 22.16 mm, mean disease duration of 4.3 years, and 74.1% had a baseline CAS of 0 or 1. Safety data indicate most adverse events were mild to moderate, with no new safety signals. SYCUME® was approved by the NMPA in March 2025 and added to the National Reimbursement Drug List on January 1, 2026. Epidemiological data show TED affects 25–40% of Graves’ disease patients, with an annual incidence of 16 per 100,000 women and 2.9 per 100,000 men, and a prevalence of 0.1–0.3%. Innovent’s broader business includes 20 launched products, 1 NDA asset, 5 in Phase 3, 19 in early stage, and over 30 partnerships valued at more than RMB 350 billion. The data is robust for clinical efficacy and operational scale, but lacks financial performance metrics.

Analysis

The announcement is generally positive and well-supported by detailed clinical trial data, including statistically significant efficacy endpoints and safety outcomes for SYCUME® in inactive TED. The inclusion of the drug in China's National Reimbursement Drug List is a realised milestone, and the company provides concrete figures on its pipeline and partnerships. However, the tone is somewhat inflated by claims such as 'filling a 70-year treatment gap' and 'substantially alleviating the financial burden,' which are not quantified or directly evidenced. No profitability, revenue, or cash flow metrics are disclosed, so the true_signal cannot exceed weak_positive. The forward-looking content is limited to ongoing follow-up and aspirations for broader clinical adoption, with most key claims already realised. There is no indication of a large new capital outlay tied to uncertain long-term returns in this release.

Risk flags

• ●The absence of detailed adverse event rates or severity breakdowns limits a full independent assessment of the safety profile, despite the company’s claim that most events were mild to moderate and no new signals emerged.
• ●No financial performance data (revenue, profit, or cash flow) for SYCUME® or the broader business is disclosed, making it impossible to assess the commercial impact or profitability of this milestone.
• ●The headline partnership value of over RMB 350 billion is presented without context on realized revenue or profit contribution, which could overstate the immediate financial benefit to shareholders.
• ●While the drug is approved and reimbursed in China, the announcement does not quantify actual patient uptake, market share, or competitive dynamics, leaving commercial execution risk unaddressed.
• ●The ongoing follow-up for the RESTORE-3 study means that longer-term safety and efficacy data are still pending, which could affect future clinical or regulatory perceptions.

Bottom line

Innovent Biologics’ SYCUME® has shown statistically significant efficacy and a favorable safety profile in a Phase 3 trial for inactive TED, with 60.4% of treated patients achieving a proptosis response at 24 weeks versus 23.5% for placebo. The drug is already approved and reimbursed in China, supporting near-term commercial potential. While the clinical data is strong and the company’s pipeline and partnership scale are impressive, the release does not provide financial performance figures or details on actual market uptake. Investors should focus on forthcoming full trial publications, real-world adoption rates, and eventual revenue disclosures to gauge the true impact. The most important takeaway is that Innovent has delivered a clinically validated, reimbursed therapy for a large, underserved patient population in China, but the financial upside remains to be demonstrated.

Announcement summary

(HKEX:01801) Innovent Biologics, Inc. announced that its recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody, SYCUME® (Teprotumumab N01 Injection, R&D code: IBI311), achieved its primary endpoint in the multicenter, randomized, double-blind, placebo-controlled Phase 3 RESTORE-3 clinical study in Chinese participants with inactive thyroid eye disease (TED). SYCUME® is the first IGF-1R antibody drug in China and the second approved worldwide, addressing a 70-year treatment gap in the domestic TED field. The drug was officially included in China's National Reimbursement Drug List on January 1, 2026, improving accessibility and reducing financial burden for patients. In RESTORE-3, 116 eligible participants were randomized in a 2:1 ratio to receive IBI311 or placebo. The primary efficacy endpoint was the proptosis response rate of the study eye at Week 24, and the key secondary endpoint was the change from baseline in proptosis of the study eye at Week 24. The baseline mean proptosis distance was 22.16 mm, and 74.1% of patients had a baseline CAS of 0 or 1 point. At Week 24, the proptosis response rate in the IBI311 group was 60.4% compared to 23.5% in the placebo group, with a treatment difference of 36.9 percentage points (p = 0.0003). The least squares mean change from baseline in study eye proptosis distance in the IBI311 group was -1.88 mm, compared to -0.88 mm in the placebo group, with a treatment difference of -1.00 mm (p < 0.0001). In non-study eyes, the proptosis response rate was 46.0% in the IBI311 group versus 19.8% in the placebo group (p = 0.0071), and the LS Mean change from baseline in proptosis distance was -1.77 mm in the IBI311 group versus -0.91 mm in the placebo group (p < 0.0001). IBI311 exhibited a favorable safety profile, with most treatment-emergent adverse events being mild to moderate and no new safety signals identified. The follow-up of the study is ongoing, with complete data to be published in future academic conferences or journals. SYCUME® was approved by the NMPA for TED in March 2025 and included in the National Reimbursement Drug List on January 1, 2026. TED affects approximately 25% to 40% of Graves' disease patients, with an annual incidence of 16 per 100,000 women and 2.9 per 100,000 men, and a prevalence of 0.1 to 0.3%. About 3-5% of patients develop sight-threatening TED. Innovent Biologics has launched 20 products, has 1 asset under NDA review, 5 assets in phase 3 or pivotal clinical trials, and 19 molecules in early clinical stage. The company has entered into more than 30 strategic partnerships with global players, representing an aggregate value of over RMB 350 billion.

Disagree with this article?